Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire

Barra L, Pope JE, Payne M

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
19487267

DOI
10.3899/jrheum.081122

Indexing Status
Subject indexing assigned by NLM

MeSH
Adalimumab; Adult; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Antirheumatic Agents /economics /therapeutic use; Arthritis, Psoriatic /drug therapy /economics /mortality; Arthritis, Rheumatoid /drug therapy /economics /mortality; Cohort Studies; Cost-Benefit Analysis; Disability Evaluation; Etanercept; Female; Follow-Up Studies; Health Surveys; Humans; Immunoglobulin G /economics /therapeutic use; Infliximab; Male; Middle Aged; Outcome Assessment (Health Care) /methods /statistics & numerical data; Receptors, Tumor Necrosis Factor /therapeutic use; Retrospective Studies; Spondylitis, Ankylosing /drug therapy /economics /mortality; Treatment Outcome; Tumor Necrosis Factor-alpha /antagonists & inhibitors

AccessionNumber
22009102576

Date bibliographic record published
03/02/2010